Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q4KMQ2
UPID:
ANO6_HUMAN
Alternative names:
Small-conductance calcium-activated nonselective cation channel; Transmembrane protein 16F
Alternative UPACC:
Q4KMQ2; A6NNM6; B9EGG0; E7ENK4; E9PB30; E9PCT2; Q8N3Q2
Background:
Anoctamin-6, also known as a small-conductance calcium-activated nonselective cation channel, plays a pivotal role in cellular processes by regulating phospholipid scrambling in platelets and osteoblasts. This activity is crucial for blood clotting and bone mineralization, respectively. Additionally, Anoctamin-6 is implicated in the body's response to SARS-CoV-2 infection by facilitating virus-induced cell fusion.
Therapeutic significance:
The association of Anoctamin-6 with Scott syndrome, a bleeding disorder, underscores its therapeutic potential. Targeting Anoctamin-6 could lead to innovative treatments for this condition and possibly other phospholipid scrambling-related diseases.